Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.62 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | MPL | P40238 | 2/20 | 0.40 |
| ▸ | PDE2A | O00408 | 2/20 | 0.40 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.37 |
| ▸ | PNMT | P11086 | 1/20 | 0.37 |
| ▸ | MPO | P05164 | 1/20 | 0.36 |
| ▸ | TPO | P07202 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20472553 | 0.86 | IDO1 (0.61) | IDO1TAAR1CA1CA2CA9 | |
| SCHEMBL16894138 | 0.85 | MAOB (0.51) | IDO1TAAR1MAOBKIF11 | |
| SCHEMBL18266405 | 0.84 | IDO1 (0.46) | IDO1TAAR1CA1CA2CA9 | |
| SCHEMBL18266564 | 0.84 | IDO1 (0.46) | IDO1TAAR1CA1CA2CA9 | |
| Hydrochloric Acid SCHEMBL5178051 | 0.84 | IDO1 (0.64) | IDO1TAAR1CA1CA2CA9 | |
| SCHEMBL507107 | 0.83 | IDO1 (0.62) | IDO1TAAR1MAOBMPLPDE2A | |
| SCHEMBL8101172 | 0.82 | IDO1 (0.43) | IDO1MAOBKIF11 | |
| Hydrochloric Acid SCHEMBL30525006 | 0.82 | IDO1 (0.66) | IDO1TAAR1MAOBMPLPDE2A | |
| SCHEMBL18602429 | 0.81 | IDO1 (0.59) | IDO1TAAR1CA1CA2CA9 | |
| SCHEMBL42905 | 0.79 | IDO1 (0.62) | IDO1TAAR1CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 264 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | claimed |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | AZEVAN PHARMACEUTICALS, INC. (US) | 2022-05-03 | — | — | US | claimed |
| EP-3351104-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF INTERMITTENT EXPLOSIVE DISORDER | AZEVAN PHARMACEUTICALS INC (US) | 2020-12-09 | — | — | EP | claimed |
| US-9597314-B2 | Beta-lactamylalkanoic acids for treating premenstrual disorders | AZEVAN PHARMACEUTICALS, INC. (US) | 2017-03-21 | — | — | US | claimed |
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | claimed |
| CN-101166730-A | Cinnoline compounds and their use as liver X receptor modilators | WYETH CORP (US) | 2008-04-23 | — | — | CN | claimed |
| US-6331649-B1 | REDUCING AN OXIME BY CATALYTIC HYDROGENTATION IN SOLVENT CONTAINING AN ACID | CENTRAL GLASS COMPANY, LIMITED (JP) | 2001-12-18 | — | — | US | claimed |
| EP-4735422-A1 | SUBSTITUTED CYCLIC COMPOUNDS AND METHODS OF TREATING PHENYLKETONURIA AND OTHER AMINO ACIDURIAS | Sanofi (FR) | 2026-05-06 | — | — | EP | disclosed |
| US-20250074909-A1 | AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2025-03-06 | — | — | US | disclosed |
| WO-2025006827-A1 | SUBSTITUTED CYCLIC COMPOUNDS AND METHODS OF TREATING PHENYLKETONURIA AND OTHER AMINO ACIDURIAS | GENZYME CORPORATION (US) | 2025-01-02 | — | — | WO | disclosed |
| US-12157733-B2 | Aminotriazolopyridines as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-12-03 | — | — | US | disclosed |
| EP-3626718-B1 | FIVE-MEMBERED-FUSED-SIX-MEMBERED AZA-AROMATIC RING COMPOUND, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF | UNIV XIAMEN (CN) | 2024-05-15 | — | — | EP | disclosed |
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | AZEVAN PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| US-20020013500-A1 | Process for producing trifluoromethylbenzylamines | CENTRAL GLASS COMPANY, LIMITED (JP) | 2002-01-31 | — | — | US | disclosed |
| US-6331649-B1 | REDUCING AN OXIME BY CATALYTIC HYDROGENTATION IN SOLVENT CONTAINING AN ACID | CENTRAL GLASS COMPANY, LIMITED (JP) | 2001-12-18 | — | — | US | disclosed |
| EP-1151990-A1 | Substituted N-arylmethylamino derivatives of cyclobutene-3, 4-diones | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-11-07 | — | — | EP | disclosed |
| CN-1230173-A | Substituted N-arylmethylamino derivatives of cyclobutene-3,-4-diones | AMERICAN HOME PROD (US) | 1999-09-29 | — | — | CN | disclosed |
| EP-0934257-A1 | SUBSTITUTED N-ARYLMETHYLAMINO DERIVATIVES OF CYCLOBUTENE-3,4-DIONES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1999-08-11 | — | — | EP | disclosed |
| US-5780505-A | ADMINISTERING AS SMOOTH MUSCLE RELAXANT | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-07-14 | — | — | US | disclosed |
| WO-1998002413-A1 | SUBSTITUTED N-ARYLMETHYLAMINO DERIVATIVES OF CYCLOBUTENE-3,4-DIONES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1998-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115553-A1 | COMPOSITIONS AND METHODS FOR TREATING BRAIN INJURY | FABP7, PYGB, CHAT | IDO1 3872/4885TAAR1 3840/4885CA1 55/4885 |
| US-20020013500-A1 | Process for producing trifluoromethylbenzylamines | MAOB, CYP2F1, AGL | IDO1 49/4885TAAR1 137/4885CA1 1242/4885 |
| US-20250074909-A1 | AMINOTRIAZOLOPYRIDINES AS KINASE INHIBITORS | RIPK1, RIPK3, RIPK4 | IDO1 886/4885TAAR1 1549/4885CA1 4431/4885 |
| US-11319306-B2 | Compositions and methods for treating neurodegenerative diseases | HTT, AVPR2, AVPR1B | IDO1 2561/4885TAAR1 173/4885CA1 1001/4885 |
| US-12157733-B2 | Aminotriazolopyridines as kinase inhibitors | RIPK1, RIPK3, RIPK4 | IDO1 886/4885TAAR1 1549/4885CA1 4431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.